 Enzyme Inhibitors
"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1982 | 0 | 1 | 1 | | 1987 | 2 | 0 | 2 | | 1990 | 0 | 1 | 1 | | 1995 | 2 | 8 | 10 | | 1996 | 3 | 18 | 21 | | 1997 | 5 | 17 | 22 | | 1998 | 7 | 14 | 21 | | 1999 | 1 | 21 | 22 | | 2000 | 7 | 21 | 28 | | 2001 | 4 | 25 | 29 | | 2002 | 8 | 39 | 47 | | 2003 | 9 | 28 | 37 | | 2004 | 6 | 20 | 26 | | 2005 | 9 | 17 | 26 | | 2006 | 6 | 20 | 26 | | 2007 | 8 | 7 | 15 | | 2008 | 3 | 17 | 20 | | 2009 | 8 | 15 | 23 | | 2010 | 10 | 8 | 18 | | 2011 | 6 | 12 | 18 | | 2012 | 3 | 12 | 15 | | 2013 | 5 | 10 | 15 | | 2014 | 7 | 7 | 14 | | 2015 | 6 | 5 | 11 | | 2016 | 5 | 5 | 10 | | 2017 | 7 | 1 | 8 | | 2018 | 9 | 5 | 14 | | 2019 | 9 | 4 | 13 | | 2020 | 6 | 3 | 9 | | 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Kim Y, Wower J, Maltseva N, Chang C, Jedrzejczak R, Wilamowski M, Kang S, Nicolaescu V, Randall G, Michalska K, Joachimiak A. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun Biol. 2021 02 09; 4(1):193.
-
Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 01 23; 397(10271):281-292.
-
Pan M, Zheng Q, Yu Y, Ai H, Xie Y, Zeng X, Wang C, Liu L, Zhao M. Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative. Nat Commun. 2021 01 05; 12(1):121.
-
You Q, Cheng AY, Gu X, Harada BT, Yu M, Wu T, Ren B, Ouyang Z, He C. Direct DNA crosslinking with CAP-C uncovers transcription-dependent chromatin organization at high resolution. Nat Biotechnol. 2021 02; 39(2):225-235.
-
Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz RZ, Peer CJ, Figg WD, Chai CLL, Miners JO, Chan ECY. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. J Pharmacol Exp Ther. 2020 09; 374(3):438-451.
-
Baran M, Grimes KD, Sibbald PA, Fu P, Boshoff HIM, Wilson DJ, Aldrich CC. Development of small-molecule inhibitors of fatty acyl-AMP and fatty acyl-CoA ligases in Mycobacterium tuberculosis. Eur J Med Chem. 2020 Sep 01; 201:112408.
-
Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, Qin X, Prince E, Xie J, Qin H, Li W, Shen C, Sun J, Kulkarni P, Weng H, Huang H, Chen Z, Zhang B, Wu X, Olsen MJ, Müschen M, Marcucci G, Salgia R, Li L, Fathi AT, Li Z, Mulloy JC, Wei M, Horne D, Chen J. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020 07 13; 38(1):79-96.e11.
-
Salvatore M, Laplante JM, Soave R, Orfali N, Plate M, van Besien K, St George K. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020 Aug; 22(4):e13336.
-
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
-
Kinloch AJ, Cascino MD, Dai J, Bermea RS, Ko K, Vesselits M, Dragone LL, Mor Vaknin N, Legendre M, Markovitz DM, Okoreeh MK, Townsend MJ, Clark MR. Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus. 2020 May; 29(6):569-577.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|